340B hospitals' annualized losses due to drug makers contract pharmacy restrictions grew sharply during Q1 2022, a survey found.

Survey: Hospitals’ Losses from 340B Contract Pharmacy Restrictions Ballooned During Q1 2022

The financial impact to 340B hospitals due to drug manufacturers’ restrictions on contract pharmacy more than doubled between December 2021 and March 2022, a new survey shows.

Hospital trade group 340B Health said the median annualized loss of contract pharmacy savings to disproportionate share (DSH) hospitals, rural referral centers (RRCs), and sole community hospitals (SCHs) rose from $1 million in December (when only eight manufacturers had restrictions) to $2.2 million in March (by which time the number of manufacturers had risen to 14). Two more manufacturers have imposed conditions since then. Ten percent of such hospitals said they expect annual losses of $21 million or more.

The financial impact to 340B hospitals due to drug manufacturers’ restrictions on contract pharmacy more than doubled between December 2021 and March 2022, a new survey shows.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report